- Home
- QUAD vs LYEL Comparison
QUAD vs LYEL Comparison
Compare QUAD & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUAD
- LYEL
- Stock Information
- Founded
- QUAD 1971
- LYEL 2018
- Country
- QUAD United States
- LYEL United States
- Employees
- QUAD N/A
- LYEL N/A
- Industry
- QUAD Publishing
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- QUAD Consumer Discretionary
- LYEL Health Care
- Exchange
- QUAD Nasdaq
- LYEL Nasdaq
- Market Cap
- QUAD 292.2M
- LYEL 253.2M
- IPO Year
- QUAD 2010
- LYEL 2021
- Fundamental
- Price
- QUAD $5.94
- LYEL $17.23
- Analyst Decision
- QUAD Strong Buy
- LYEL Hold
- Analyst Count
- QUAD 2
- LYEL 3
- Target Price
- QUAD $9.30
- LYEL $16.67
- AVG Volume (30 Days)
- QUAD 189.1K
- LYEL 36.6K
- Earning Date
- QUAD 10-28-2025
- LYEL 11-12-2025
- Dividend Yield
- QUAD 5.05%
- LYEL N/A
- EPS Growth
- QUAD N/A
- LYEL N/A
- EPS
- QUAD N/A
- LYEL N/A
- Revenue
- QUAD $2,584,500,000.00
- LYEL $60,000.00
- Revenue This Year
- QUAD N/A
- LYEL N/A
- Revenue Next Year
- QUAD N/A
- LYEL N/A
- P/E Ratio
- QUAD N/A
- LYEL N/A
- Revenue Growth
- QUAD N/A
- LYEL 11.11
- 52 Week Low
- QUAD $4.50
- LYEL $7.65
- 52 Week High
- QUAD $9.13
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- QUAD 48.31
- LYEL 56.81
- Support Level
- QUAD $5.69
- LYEL $16.00
- Resistance Level
- QUAD $5.92
- LYEL $18.60
- Average True Range (ATR)
- QUAD 0.18
- LYEL 1.13
- MACD
- QUAD 0.04
- LYEL -0.15
- Stochastic Oscillator
- QUAD 70.91
- LYEL 41.22
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.